TFR1 upregulation and FPN downregulation have been reported in various cancer cell lines (Gao et al., 2015; Torti and Torti, 2019); therefore, ferroptosis-related genetic biomarkers may be considered potential therapeutic biomarkers for cancer treatment. This evidence concerns the gene SLC40A1 and cancer.